-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RVU-120 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RVU-120 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RVU-120 in Triple-Negative Breast Cancer (TNBC) Drug Details: RVU-120...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RVU-120 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RVU-120 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RVU-120 in Solid Tumor Drug Details: RVU-120 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Evorpacept in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Evorpacept in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Evorpacept in Mantle Cell Lymphoma Drug Details: Evorpacept is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Primary Mediastinal B-Cell Lymphoma Drug Details:...
-
Product Insights
Wilms’ Tumor (Nephroblastoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Wilms' Tumor (Nephroblastoma) - Drugs In Development, 2023’, provides an overview of the Wilms' Tumor (Nephroblastoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Wilms' Tumor (Nephroblastoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Myelofibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myelofibrosis - Drugs In Development, 2023’, provides an overview of the Myelofibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Lung Adenocarcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Lung Adenocarcinoma - Drugs In Development, 2023’, provides an overview of the Lung Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lung Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Volixibat Potassium in Pruritus
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Volixibat Potassium in Pruritus Drug Details: Volixibat potassium (SHP-626, LUM-002) is under development for primary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RVU-120 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RVU-120 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RVU-120 in Solid Tumor Drug Details:RVU-120 is under development for the treatment of...
-
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...